Ritlecitinib - CISMeF

Preferred Label : Ritlecitinib;

NCIt related terms : JAK3 Inhibitor PF-06651600;

NCIt definition : An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.;

UNII : 2OYE00PC25;

InChIKey : CBRJPFGIXUFMTM-WDEREUQCSA-N;

CAS number : 1792180-81-4;

Molecule name : PF-06651600; PF 06651600;

NCI Metathesaurus CUI : CL970401;

Details

Origin ID

C161783;

UMLS CUI

C5418278;

Currated CISMeF NLP mapping
- Ritlecitinib [SMS substance]
See also inter- (CISMeF)
- janus kinase 3 [MeSH Descriptor]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- PF-06651600 [MeSH Supplementary Concept]
- ritlecitinib [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Tyrosine-Protein Kinase JAK3 [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients